Published in

Elsevier, Brazilian Journal of Infectious Diseases, 5(14), p. 519-525, 2010

DOI: 10.1016/s1413-8670(10)70104-5

Elsevier, Brazilian Journal of Infectious Diseases, 5(14), p. 519-525

DOI: 10.1590/s1413-86702010000500017

Links

Tools

Export citation

Search in Google Scholar

Response predictors to treatment with pegylated interferon in chronic hepatitis B

Journal article published in 2010 by Ferreira,Paulo Roberto Abrão, Tenore,Simone de Barros, Simone de Barros Tenore, Paulo Roberto Abrão Ferreira ORCID, Simone de Barros Tenore
This paper is made freely available by the publisher.
This paper is made freely available by the publisher.

Full text: Download

Green circle
Preprint: archiving allowed
Upload
Green circle
Postprint: archiving allowed
Upload
Green circle
Published version: archiving allowed
Upload
Policy details
Data provided by SHERPA/RoMEO

Abstract

The clinical and epidemiological importance of chronic B hepatitis is currently unquestionable as a cause of end-stage liver disease and hepatocellular carcinoma. Recently, predictors of treatment response of this disease have been studied, both before and during the course of medication. Therapy stopping rules have been proposed, which may be useful in patients presenting poor treatment tolerance. This review discusses the treatment response predictors usefulness, with emphasis on ALT, quantitative HBsAg and HBeAg, quantitative HBV-DNA and HBV genotype.